JP2019502500A - 磁気パルスのシーケンスによる上皮の完全性の向上 - Google Patents
磁気パルスのシーケンスによる上皮の完全性の向上 Download PDFInfo
- Publication number
- JP2019502500A JP2019502500A JP2018538723A JP2018538723A JP2019502500A JP 2019502500 A JP2019502500 A JP 2019502500A JP 2018538723 A JP2018538723 A JP 2018538723A JP 2018538723 A JP2018538723 A JP 2018538723A JP 2019502500 A JP2019502500 A JP 2019502500A
- Authority
- JP
- Japan
- Prior art keywords
- pulses
- corneal
- cornea
- rate
- magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004087 cornea Anatomy 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000008859 change Effects 0.000 claims abstract description 30
- 230000004888 barrier function Effects 0.000 claims abstract description 25
- 210000005081 epithelial layer Anatomy 0.000 claims abstract description 18
- 230000001965 increasing effect Effects 0.000 claims abstract description 17
- 230000035699 permeability Effects 0.000 claims abstract description 12
- 230000003247 decreasing effect Effects 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 27
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 22
- 206010013774 Dry eye Diseases 0.000 claims description 22
- 231100000478 corneal permeability Toxicity 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 206010023332 keratitis Diseases 0.000 claims description 11
- 230000035515 penetration Effects 0.000 claims description 10
- 230000009931 harmful effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 230000007360 epithelial dysfunction Effects 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 235000008113 selfheal Nutrition 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 14
- 230000007423 decrease Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 11
- 210000000981 epithelium Anatomy 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000004890 epithelial barrier function Effects 0.000 description 7
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 210000003560 epithelium corneal Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012014 optical coherence tomography Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 210000004082 barrier epithelial cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004887 epithelial permeability Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 230000008378 epithelial damage Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000003826 superficial keratitis Diseases 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000035620 Eye penetration Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical class O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 230000007929 epithelial cell-cell adhesion Effects 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/0079—Methods or devices for eye surgery using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Radiology & Medical Imaging (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Optics & Photonics (AREA)
- Electromagnetism (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Magnetic Treatment Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (20)
- 上皮層を処置するための磁気装置であって、磁気パルス発生器を含み、パルスは、前記発生器から最大10cmの距離で最大3Tの振幅および50μs〜2000μsの持続時間を有し、前記振幅は、絶対値で少なくとも200T/秒の変化率で前記パルスの間に増加する、磁気装置。
- 前記振幅が0.05T〜2Tである、請求項1に記載の装置。
- 前記変化率が、絶対値で少なくとも2,000T/秒である、請求項1に記載の装置。
- 前記変化率が、絶対値で最大20,000T/秒である、請求項1に記載の装置。
- 前記パルスを最大200パルス/秒の速度で生成する、請求項1に記載の装置。
- 上皮層の透過性を低下させる方法であって、
最大3Tの振幅および50μs〜2000μsの持続時間を有する磁気パルスを前記層の近傍で生成することを含み、
前記振幅は、少なくとも200T/秒の変化率で前記パルスの間に増加する、方法。 - 上皮層の完全性の低下または透過性の増加に関連する状態を非侵襲的に処置する方法であって、
最大3T、好ましくは0.05T〜2Tの振幅および50μs〜2000μsの持続時間を有する磁気パルスを前記上皮層の近傍で生成することを含み、
前記振幅は、絶対値で少なくとも200T/秒の変化率で前記パルスの間に増加する、方法。 - 前記変化率が、絶対値で少なくとも2,000T/秒である、請求項6または7に記載の方法。
- 前記変化率が、絶対値で最大20,000T/秒である、請求項6または7に記載の方法。
- 前記パルスが、最大200パルス/秒の速度で生成される、請求項6または7に記載の方法。
- 前記パルスが、0.5〜20秒間続く連続で生成される、請求項6または7に記載の方法。
- 前記パルスが、連続して生成された後に磁気信号なしで遮断される、請求項11に記載の方法。
- 前記パルスの連続および前記遮断が、1つのセッション中に繰り返される、請求項12に記載の方法。
- 前記上皮層がヒトの眼の角膜に関連する、請求項1に記載の装置。
- 前記上皮層がヒトの眼の角膜に関連する、請求項6または7に記載の方法。
- 上皮細胞、内皮細胞、神経細胞、および間質細胞からなる群から選択される角膜細胞を処置することを含む、請求項7に記載の方法。
- 前記角膜の近傍で最大3Tの振幅および50μs〜2000μsの持続時間を有する磁気パルスを生成することを含み、
前記振幅は絶対値で少なくとも200T/秒の変化率で前記パルスの間に増加する、
請求項15に記載の角膜の完全性を向上または透過性を低下させる方法。 - 前記角膜の近傍で角膜の表面に対して垂直な方向に0.05〜2Tの強度、好ましくは0.1〜1.5Tの強度を有する磁気パルスを前記角膜の近傍に印加することを含み、
前記パルスが50μs〜2000μsの持続時間を有し、5〜500パルス/秒の速度で生成される、請求項17に記載の角膜の処置方法。 - 前記パルスが、0.5〜20秒間続く連続で生成され、続いて磁気信号なしで遮断され、前記連続および前記遮断は、1回の処置セッション中に繰り返される、請求項18に記載の方法。
- 眼乾燥症、乾性角膜炎、角膜炎、角膜上皮機能障害、糖尿病に関連する角膜のバリア機能の低下、老化による角膜透過性の増加に関連する状態、角膜表面の軽微な病変、コンタクトレンズの着用に関連する状態、角膜の自己治癒能力の低下、汚染された環境からの眼への有害物質の浸透、減弱した抗浸透系、および角膜関連炎症からなる群から選択される状態を処置または予防することを含む、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL243686 | 2016-01-19 | ||
IL243686A IL243686B (en) | 2016-01-19 | 2016-01-19 | Device for increasing the integrity of the eye epithelium using magnetic pulses |
PCT/IL2016/051392 WO2017125909A1 (en) | 2016-01-19 | 2016-12-28 | Enhancing epithelial integrity by a sequence of magnetic pulses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019502500A true JP2019502500A (ja) | 2019-01-31 |
JP7291370B2 JP7291370B2 (ja) | 2023-06-15 |
Family
ID=57300901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018538723A Active JP7291370B2 (ja) | 2016-01-19 | 2016-12-28 | 磁気パルスのシーケンスによる上皮の完全性の向上 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11083908B2 (ja) |
EP (1) | EP3405149A4 (ja) |
JP (1) | JP7291370B2 (ja) |
CN (1) | CN108697532B (ja) |
IL (1) | IL243686B (ja) |
WO (1) | WO2017125909A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL253677B2 (en) | 2017-07-26 | 2023-06-01 | Epitech Mag Ltd | A magnetic device for the treatment of living tissues |
WO2023076431A1 (en) * | 2021-10-26 | 2023-05-04 | David Pon | Treatment of non-ocular diseases/disorders by delivery of electromagnetic energy to ocular tissue |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249488A1 (en) * | 2009-03-30 | 2010-09-30 | MagneGene, Inc. | Method of contactless magnetic electroporation |
WO2014181327A1 (en) * | 2013-05-06 | 2014-11-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Device and method for reducing the permeability of the cornea |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1076126A1 (ru) | 1982-04-29 | 1984-02-29 | 2-Ой Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова | Способ лечени заболеваний периферической нервной системы |
US5055627A (en) | 1985-01-07 | 1991-10-08 | Chemical Research & Licensing Company | Process for the preparation of cumene |
US5135466A (en) | 1988-08-18 | 1992-08-04 | Fedorov Svjatoslav N | Method for treatment of diseases of the optic tract and a device for carrying said method into effect |
GB2271931A (en) | 1992-10-29 | 1994-05-04 | Benjamin Israel Sacks | Magnetic stimulator for medical use |
US5725471A (en) | 1994-11-28 | 1998-03-10 | Neotonus, Inc. | Magnetic nerve stimulator for exciting peripheral nerves |
WO1999019020A1 (en) | 1997-10-15 | 1999-04-22 | Minrad Inc. | Magnetically compatible peripheral nerve stimulator |
WO2001078829A2 (en) | 2000-04-12 | 2001-10-25 | Neotonus, Inc. | Magnetic nerve stimulator utilizing vertically overlapping cores |
WO2004036377A2 (en) | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Configuring and testing treatment therapy parameters for a medical device system |
AU2005237539A1 (en) | 2004-04-26 | 2005-11-10 | Dimino Andre'a | Electromagnetic treatment induction apparatus and method |
US7601115B2 (en) * | 2004-05-24 | 2009-10-13 | Neuronetics, Inc. | Seizure therapy method and apparatus |
JP2005334586A (ja) | 2004-05-27 | 2005-12-08 | Takemitsu Yamashita | 磁気治療器 |
US7857746B2 (en) | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
WO2006107951A2 (en) | 2005-04-04 | 2006-10-12 | Ernest Paul Pattern | Digital electromagnetic pulse generator |
US7727138B2 (en) | 2005-07-07 | 2010-06-01 | Alfredo Alvarado | Magnetic apparatus for the treatment of cataracts and other eye conditions |
US8932195B2 (en) | 2006-06-30 | 2015-01-13 | Research Foundation Of The City University Of New York | Process and apparatus for improving neuronal performance |
US8834341B2 (en) | 2007-05-02 | 2014-09-16 | Kenneth Stephen Olree | Coil optimization for magnetic stimulation |
KR100846070B1 (ko) | 2007-07-18 | 2008-07-11 | 장복현 | 레이저 저주파 부항기 이온 영동 자석 침의 조화 치료기 |
RU2368405C1 (ru) | 2008-05-22 | 2009-09-27 | Илья Иосифович Гамер | Устройство для воздействия магнитным полем (варианты) |
KR101134657B1 (ko) | 2008-12-15 | 2012-04-09 | 강희정 | 자성체를 이용한 혈류량 개선 장치 |
US8954166B2 (en) | 2009-06-21 | 2015-02-10 | Eugene Eustis Pettinelli | Induced modulation of neuronal transmission |
WO2011059986A1 (en) | 2009-11-12 | 2011-05-19 | Neosync, Inc. | Systems and methods for neuro-eeg synchronization therapy |
CA2817589A1 (en) | 2010-11-16 | 2012-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
RU2011114847A (ru) | 2011-04-15 | 2012-10-20 | Общество с ограниченной ответственностью "Фонд проектных решений" (RU) | Способ лечения периферических парезов и параличей |
US9649502B2 (en) | 2011-11-14 | 2017-05-16 | Neosync, Inc. | Devices and methods of low frequency magnetic stimulation therapy |
KR101586684B1 (ko) | 2011-11-15 | 2016-01-20 | 조귀형 | 안구 마사지 장치 |
US8548599B2 (en) | 2011-11-16 | 2013-10-01 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US9802062B2 (en) | 2012-04-05 | 2017-10-31 | Matthew Bujak | Method, system and use for therapeutic ultrasound |
JP5887191B2 (ja) * | 2012-04-19 | 2016-03-16 | 株式会社トーメーコーポレーション | 角膜撮影装置および角膜撮影方法 |
CN104755135B (zh) | 2012-07-30 | 2017-03-22 | 神磁医学股份有限公司 | 用以治疗神经系统失调的磁刺激装置与方法 |
RU2499614C1 (ru) | 2012-09-21 | 2013-11-27 | Федеральное государственное бюджетное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения Российской Федерации (ФГБУ "СарНИИТО" Минздрава России) | Способ электромагнитной стимуляции центральной и периферической нервной системы |
US9265956B2 (en) | 2013-03-08 | 2016-02-23 | Oculeve, Inc. | Devices and methods for treating dry eye in animals |
US10369373B2 (en) | 2013-03-11 | 2019-08-06 | The Regents Of The University Of California | Portable transcutaneous magnetic stimulator and systems and methods of use thereof |
US9114246B2 (en) | 2013-03-15 | 2015-08-25 | University Of Rochester | Spinal nerve stimulation rings for rehabilitation of patients with spinal trauma and stroke |
NZ704579A (en) | 2013-04-19 | 2018-10-26 | Oculeve Inc | Nasal stimulation devices and methods |
US9427224B1 (en) | 2013-05-14 | 2016-08-30 | Dhiraj JEYANANDARAJAN | Apparatus and methods for surgical access |
US10065047B2 (en) | 2013-05-20 | 2018-09-04 | Nervive, Inc. | Coordinating emergency treatment of cardiac dysfunction and non-cardiac neural dysfunction |
CN203276182U (zh) | 2013-06-12 | 2013-11-06 | 浙江海洋学院 | 电磁按摩键盘 |
KR101518036B1 (ko) | 2013-09-06 | 2015-05-20 | 비엠생명공학(주) | 안구건조증 치료장치 |
CA2857555A1 (en) | 2014-04-01 | 2015-10-01 | William F. Stubbeman | Method and system for therapeutic brain stimulation using electromagnetic pulses |
EP3142746A1 (en) | 2014-05-13 | 2017-03-22 | The Cleveland Clinic Foundation | System and method for micromagnetic stimulation of the peripheral nervous system |
WO2016015025A1 (en) | 2014-07-25 | 2016-01-28 | Oculeve, Inc. | Stimulation patterns for treating dry eye |
US20160158562A1 (en) | 2014-12-09 | 2016-06-09 | Pacesetter, Inc. | Systems and methods for neurostimulation of a peripheral nerve |
RU2581495C1 (ru) | 2015-02-26 | 2016-04-20 | Федеральное государственное бюджетное учреждение "Государственный научный центр Российской Федерации - Федеральный медицинский биофизический центр имени А.И. Бурназяна" (ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России) | Способ лечения синдрома сухого глаза |
JP2018517517A (ja) | 2015-06-16 | 2018-07-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 涙産生刺激用の鼻涙インプラント及び関連方法 |
EP4293828A3 (en) | 2015-09-11 | 2024-01-31 | Nalu Medical, Inc. | Apparatus for peripheral or spinal stimulation |
ITUB20154761A1 (it) | 2015-10-29 | 2017-04-29 | Resono Ophthalmic S R L | Sistema di elettrodo e relativo dispositivo per il trattamento di patologie dell?occhio, in particolare dell?occhio secco |
US10874871B2 (en) | 2015-11-09 | 2020-12-29 | Axilum Robotics (Societe Par Actions Simpl | Magnetic stimulation device comprising a force-sensing resistor |
US10695219B2 (en) | 2016-04-08 | 2020-06-30 | ThermiGen, LLC | Apparatus and method for treatment of dry eye using radio frequency heating |
WO2017208168A2 (en) | 2016-05-31 | 2017-12-07 | Lab Schöpfergeist Ag | Strap arrangement for a nerve stimulator |
KR101860030B1 (ko) | 2016-07-04 | 2018-05-23 | 단국대학교 천안캠퍼스 산학협력단 | 저출력 레이저 치료법을 이용한 안구건조증 치료기기 |
CN106023936B (zh) | 2016-07-28 | 2018-10-23 | 武汉华星光电技术有限公司 | 扫描驱动电路及具有该电路的平面显示装置 |
US20180161579A1 (en) | 2016-12-01 | 2018-06-14 | Oculeve, Inc. | Extranasal stimulation devices and methods |
-
2016
- 2016-01-19 IL IL243686A patent/IL243686B/en unknown
- 2016-12-28 EP EP16886201.9A patent/EP3405149A4/en active Pending
- 2016-12-28 WO PCT/IL2016/051392 patent/WO2017125909A1/en active Application Filing
- 2016-12-28 JP JP2018538723A patent/JP7291370B2/ja active Active
- 2016-12-28 CN CN201680081997.5A patent/CN108697532B/zh active Active
-
2018
- 2018-07-19 US US16/039,659 patent/US11083908B2/en active Active
-
2021
- 2021-08-09 US US17/397,372 patent/US20220023654A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249488A1 (en) * | 2009-03-30 | 2010-09-30 | MagneGene, Inc. | Method of contactless magnetic electroporation |
WO2014181327A1 (en) * | 2013-05-06 | 2014-11-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Device and method for reducing the permeability of the cornea |
Also Published As
Publication number | Publication date |
---|---|
JP7291370B2 (ja) | 2023-06-15 |
US11083908B2 (en) | 2021-08-10 |
IL243686B (en) | 2022-05-01 |
EP3405149A1 (en) | 2018-11-28 |
CN108697532B (zh) | 2022-05-03 |
US20190046810A1 (en) | 2019-02-14 |
IL243686A0 (en) | 2016-07-31 |
WO2017125909A8 (en) | 2017-12-28 |
WO2017125909A1 (en) | 2017-07-27 |
EP3405149A4 (en) | 2019-09-04 |
CN108697532A (zh) | 2018-10-23 |
US20220023654A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sehic et al. | Electrical stimulation as a means for improving vision | |
Lombardo et al. | Randomized controlled trial comparing transepithelial corneal cross-linking using iontophoresis with the Dresden protocol in progressive keratoconus | |
Hirata et al. | Hyperosmolar tears induce functional and structural alterations of corneal nerves: electrophysiological and anatomical evidence toward neurotoxicity | |
Wong et al. | Suppression of metabolic activity caused by infantile strabismus and strabismic amblyopia in striate visual cortex of macaque monkeys | |
Medeiros et al. | The impact of photorefractive keratectomy and mitomycin C on corneal nerves and their regeneration | |
Yang et al. | Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma | |
US20220023654A1 (en) | Enhancing epithelial integrity by a sequence of magnetic pulses | |
Biermann et al. | Evaluation of intraocular pressure elevation in a modified laser-induced glaucoma rat model | |
Lombardo et al. | Novel technique of Transepithelial corneal cross‐linking using iontophoresis in progressive keratoconus | |
JP2005535691A (ja) | 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用 | |
Modarres et al. | Vitrectomy and release of presumed epipapillary vitreous traction for treatment of nonarteritic anterior ischemic optic neuropathy associated with partial posterior vitreous detachment | |
Ben-Shlomo et al. | Pattern electroretinography in a rat model of ocular hypertension: functional evidence for early detection of inner retinal damage | |
US10058710B2 (en) | Device and method for reducing the permeability of the cornea | |
RU2581495C1 (ru) | Способ лечения синдрома сухого глаза | |
Amano et al. | Corneal epithelial changes after excimer laser photorefractive keratectomy | |
Yildirim et al. | Evaluation of color-changing effect and complications after Nd: YAG laser application on iris surface | |
RU2750902C1 (ru) | Способ проведения кросслинкинга роговичного коллагена и одновременной имплантации интрастромальных роговичных сегментов на парном глазу у пациентов с разными стадиями кератоконуса | |
RU2682494C1 (ru) | Способ лечения кератэктазий методом импульсного акселерированного ультрафиолетового кросслинкинга роговицы | |
RU2699206C1 (ru) | Способ лечения дефектов роговицы с помощью аутологичного тромбофибринового сгустка | |
Vastardis et al. | Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up | |
Amano et al. | Specular microscopic evaluation of the corneal epithelium after excimer laser photorefractive keratectomy | |
RU2289376C1 (ru) | Способ лечения врожденной миопии у детей | |
RU2645126C1 (ru) | Способ коррекции миопии | |
RU2392982C1 (ru) | Способ лечения диабетической микроангиопатии сетчатки и диабетической ретинопатии | |
Wagner et al. | Monocular transcorneal electrical stimulation induces ciliary muscle thickening in contralateral eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191217 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20191217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191218 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220607 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220607 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220614 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220616 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220715 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220721 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220929 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221108 |
|
C30 | Protocol of an oral hearing |
Free format text: JAPANESE INTERMEDIATE CODE: C30 Effective date: 20230131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230206 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7291370 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |